You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Real-world efficacy and safety of nivolumab in previously-treated metastatic renal cell carcinoma, and association between immune-related adverse events and survival: the Italian expanded access program
|
|---|---|
| Published in |
Journal for Immunotherapy of Cancer, April 2019
|
| DOI | 10.1186/s40425-019-0579-z |
| Pubmed ID | |
| Authors |
Elena Verzoni, Giacomo Cartenì, Enrico Cortesi, Diana Giannarelli, Andrea De Giglio, Roberto Sabbatini, Sebastiano Buti, Sabrina Rossetti, Francesco Cognetti, Francesca Rastelli, Alberto Sobrero, Daniele Turci, Cora N. Sternberg, Camillo Porta, Federico Cappuzzo, Giampaolo Tortora, Davide Tassinari, Stefano Panni, Antonio Pazzola, Gianmarco Surico, Alessandra Raimondi, Ugo De Giorgi, Giuseppe Procopio |
X Demographics
The data shown below were collected from the profiles of 11 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 7 | 64% |
| Italy | 1 | 9% |
| Unknown | 3 | 27% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 7 | 64% |
| Practitioners (doctors, other healthcare professionals) | 2 | 18% |
| Science communicators (journalists, bloggers, editors) | 2 | 18% |
Mendeley readers
The data shown below were compiled from readership statistics for 68 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 68 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Postgraduate | 9 | 13% |
| Other | 8 | 12% |
| Researcher | 8 | 12% |
| Student > Bachelor | 6 | 9% |
| Student > Doctoral Student | 4 | 6% |
| Other | 13 | 19% |
| Unknown | 20 | 29% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 26 | 38% |
| Biochemistry, Genetics and Molecular Biology | 6 | 9% |
| Pharmacology, Toxicology and Pharmaceutical Science | 3 | 4% |
| Environmental Science | 2 | 3% |
| Immunology and Microbiology | 1 | 1% |
| Other | 3 | 4% |
| Unknown | 27 | 40% |
Attention Score in Context
This research output has an Altmetric Attention Score of 7. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 08 March 2020.
All research outputs
#5,338,778
of 25,385,509 outputs
Outputs from Journal for Immunotherapy of Cancer
#1,380
of 3,424 outputs
Outputs of similar age
#104,421
of 364,727 outputs
Outputs of similar age from Journal for Immunotherapy of Cancer
#46
of 79 outputs
Altmetric has tracked 25,385,509 research outputs across all sources so far. Compared to these this one has done well and is in the 78th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 3,424 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 15.4. This one has gotten more attention than average, scoring higher than 59% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 364,727 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 71% of its contemporaries.
We're also able to compare this research output to 79 others from the same source and published within six weeks on either side of this one. This one is in the 41st percentile – i.e., 41% of its contemporaries scored the same or lower than it.